France 2030 : Lovaltech and Aptar Pharma, Laureates of France 2030

A world-class industrial partner for the LVT-Nexus nasal delivery system:

Lovaltech and Aptar Pharma, a global specialist in pharmaceutical delivery systems, were selected as winners of a France 2030 project call.

The nasal delivery device, which is the third component of the LVT-NEXUS platform alongside the vaccine payload and the LVT-ME muco-excipient, was developed by Aptar Pharma and Lovaltech. It enables simple, needle-free nasal administration.

This website use coockies and give you the control on what you want to activate. Accept all Personnalise